post-bg-416
calendary January 17, 2025

A new drug for the treatment of a rare heart disease has been approved in the USA

The U.S. Food and Drug Administration (FDA) has approved a drug for the treatment of progressive genetic heart disease – ATTR-CM.

The drug Atturby (acoramidis) has shown its effectiveness in phase III clinical trials involving 632 patients. After 30 months of taking the study drug, there was a 42% decrease in overall mortality and the number of hospitalizations associated with cardiovascular diseases compared with placebo. 

The active pharmaceutical substance of Atturby, acoramidis, provides almost complete (more than 90%) stabilization of the protein transtiretin (TTR), which transports thyroid hormone thyroxine and vitamin A throughout the body. This protein is a complex of four subunits. Due to age-related changes or genetic mutations, TTR can break down into separate parts, which can fold incorrectly and form toxic amyloid fibrils, leading to the development of cardiomyopathy and heart failure. 

Currently, tafamidis preparations manufactured by Pfizer are used for the treatment of ATTR-CM. In the Russian market, these drugs are presented under the trade names Vindamex (registration date 07/12/2024) and Vindakel (registration date 04/13/2022). In Russia, these drugs have orphan status. 

Tafamidis is also a stabilizer of the transthyretin protein and binds to it in thyroxine binding sites, stabilizing the four-component structure of the protein and slowing its breakdown. 

According to the developer of the Atturby drug, BridgeBio, tafamidis drugs provide only 50% stabilization of TTR, and clinical research data indicate that tafamidis reduces the number of deaths and hospitalizations associated with heart disease by about 30%, which indicates a higher efficacy of the Atturby drug. 

The European Union is also considering an application for registration of Atturby. The rights to this drug in the EU belong to Bayer, which will pay BridgeBio up to $ 310 million if the drug is approved by the regulator.

 

 

References:
  1. https://pharmvestnik.ru/content/news/FDA-odobrilo-preparat-Attruby-kompanii-BridgeBio-dlya-lecheniya-redkogo-zabolevaniya-serdca.html
  2. https://grls.rosminzdrav.ru/
  3. https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages

More related posts

new-img-1

Control

Fine for spa resort in Yessentuki

Roszdravnadzor has imposed a fine of 130 thousand rubles on a spa resort in Yessentuki for improper storage of medical products…

03.03.2016
READ ARTICLE
new-img-2

Roszdravnadzor

Roszdravnadzor – patients’ rights

In 2015, Roszdravnadzor restored the rights of more than 460 thousand citizens to effective, accessible, and safe medical…

03.03.2016
READ ARTICLE
new-img-3

Regulation

The certification scheme for medical products hasn’t changed recently

Roszdravnadzor informs that the certification scheme for products in the Russian Federation is determined by Decree of the…

03.04.2016
READ ARTICLE
new-img-4

Control

Fines – Rostov region

In one and a half months of 2016, the Local Agency of Roszdravnadzor in Rostov Region imposed fines of the total amount of…

03.10.2016
READ ARTICLE
new-img-5

Control

Unregistered medical products

Two citizens were fined for selling unregistered medicinal products on the Internet in the Republic of Bashkortostan.

03.10.2016
READ ARTICLE
new-img-6

Control

Unscheduled inspection by roszdravnadzor

Roszdravnadzor started an unscheduled inspection of the Federal State-Funded Institution of Sverdlovsk Region Kirovgrad Central…

03.14.2016
READ ARTICLE
new-img-7

Medical Devices

International medical device regulators forum (IMDRF)

The delegation of the Federal Service for Surveillance in Healthcare headed by Mikhail Murashko, Head of Roszdravnadzor,…

03.17.2016
READ ARTICLE
new-img-8

Pharmaceuticals

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF”

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF” in which pills the metal wire was found.

05.18.2016
READ ARTICLE
new-img-9

Roszdravnadzor

Medical equipment stands idle in the Pskov region

Roszdravnadzor (RZN) statement: the expensive medical equipment for the total amount of 342 million rubles stands idle in…

05.19.2016
READ ARTICLE
new-img-10

Control

Hospital control Jewish autonomous region

Roszdravnadzor has audited the activity of the Regional Budgetary Public Health Facility “Central district hospital of Lenin”…

05.20.2016
READ ARTICLE